3-(4-Chlorophenyl)-4-cyano-5-ethylsulfanylthiophene-2-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 3-(4-Chlorophenyl)-4-cyano-5-ethylsulfanylthiophene-2-carboxylic acid
• 化学式: C₁₄H₁₀ClNO₂S₂
• 分子量: 323.8
• InChiKey: BABVYMQCELIWIF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  115
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• 3-Cyano-4-arylthiophenes
  申请人：ELI LILLY AND COMPANY

  公开号：EP0273602A1

  公开（公告）日：1988-07-06

  Herbicidal compounds of formula (I): x is 0-2; R is C₁-C₃ primary alkyl; R¹ is phenyl; phenyl mono-substituted with bromo, chloro, fluoro, C₁-C₃ alkyl, trifluoromethyl, tri­fluoromethoxy, or C₁-C₃ alkoxy; or phenyl disubstituted at the 2,4-, 2,6-, or 3,4-positions with bromo, chloro, or fluoro; R² is hydrogen or chloro; provided that x is 0 and R is methyl when R¹ is alkylphenyl or trifluoromethylphenyl; and R is methyl when R¹ is disubstituted phenyl are particularly useful in rice culture.

  式(I)的除草化合物：x为0-2；R为C₁-C₃一级烷基；R¹为苯基；苯单取代为溴、氯、氟、C₁-C₃烷基、三氟甲基、三氟甲氧基或C₁-C₃烷氧基；或苯二取代于2,4-、2,6-或3,4-位的溴、氯或氟；R²为氢或氯；但当R¹为烷基苯基或三氟甲基苯基时，x为0且R为甲基；当R¹为二取代苯基时，R为甲基，这些化合物在水稻栽培中特别有用。
• INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT NEUROINFLAMMATORY DISORDERS
  申请人：TABACZYNSKI David A.

  公开号：US20160303146A1

  公开（公告）日：2016-10-20

  This invention provides methods and pharmaceutical compositions that can treat neuroinflammatory disease by reducing the production of pyrophosphate intermediates produced during the biosynthesis of isoprenoids. The pyrophosphate compounds being inhibited are normally produced through the mevalonate and non-mevalonate pathways of the host vertebrate organisms and their symbiotic and pathogenic microorganisms. The methods involve administering to a patient an inhibitor of the mevalonate-dependent pathway, an inhibitor of the non-mevalonate pathway, or combination of such inhibitors.
• INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT AUTOIMMUNE DISORDERS
  申请人：TABACZYNSKI David A.

  公开号：US20160375041A1

  公开（公告）日：2016-12-29

  The invention provides methods and pharmaceutical compositions that can treat autoimmune disease by reducing the production of pyrophosphate intermediates produced during the biosynthesis of isoprenoids. The pyrophosphate compounds being inhibited are normally produced through the mevalonate and non-mevalonate pathways of the host vertebrate organisms and their symbiotic and pathogenic microorganisms. The methods involve administering to a patient an inhibitor of the mevalonate-dependent pathway, an inhibitor of the non-mevalonate pathway, or combination of such inhibitors.